{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Gazinska P"],"funding":["Cancer Research UK","Breast Cancer Now","National Institute for Health Research (NIHR)"],"pagination":["4494-4508"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9561554"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(20)"],"pubmed_abstract":["Purpose
To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)-resistant triple-negative breast cancer (TNBC) and ER+HER2- breast cancer disease.Experimental design
Following pathology review, 153 patients were identified as having residual cancer burden (RCB) II/III disease (TNBC n = 80; ER+HER2-n = 73). Baseline pre-NAC samples were available for evaluation for 32 of 80 TNBC and 36 of 73 ER+HER2- cases. Bright-field hematoxylin and eosin assessment allowed for tumor-infiltrating lymphocyte (TIL) evaluation in all cases. Multiplexed immunofluorescence was used to identify the abundance and distribution of immune cell subsets. Levels of checkpoints including PD-1/PD-L1 expression were also quantified. Findings were then validated using expression profil"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers."],"pmcid":["PMC9561554"],"funding_grant_id":["24869","C56773 / A24869","DRCRPGTD-Nov21\\100001","CL-2015-22-002"],"pubmed_authors":["Melcher A","Naidoo K","Buus R","Wesseling J","Roxanis I","Ward J","Lips E","Khan A","Milton C","Alaguthurai T","Gillett C","Iacovacci J","Gazinska P","Marafioti T","Dowsett M","Irshad S","Graham R","Akarca A","Salgado R","Haider S","Tutt A","Cheang M","Wu Y"],"additional_accession":[]},"is_claimable":false,"name":"Dynamic Changes in the NK-, Neutrophil-, and B-cell Immunophenotypes Relevant in High Metastatic Risk Post Neoadjuvant Chemotherapy-Resistant Early Breast Cancers.","description":"Purpose
To identify potential immune targets in post-neoadjuvant chemotherapy (NAC)-resistant triple-negative breast cancer (TNBC) and ER+HER2- breast cancer disease.Experimental design
Following pathology review, 153 patients were identified as having residual cancer burden (RCB) II/III disease (TNBC n = 80; ER+HER2-n = 73). Baseline pre-NAC samples were available for evaluation for 32 of 80 TNBC and 36 of 73 ER+HER2- cases. Bright-field hematoxylin and eosin assessment allowed for tumor-infiltrating lymphocyte (TIL) evaluation in all cases. Multiplexed immunofluorescence was used to identify the abundance and distribution of immune cell subsets. Levels of checkpoints including PD-1/PD-L1 expression were also quantified. Findings were then validated using expression profil","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-28T03:45:45.788Z","creation":"2025-04-06T00:51:07.62Z"},"accession":"S-EPMC9561554","cross_references":{"pubmed":["36161312"],"doi":["10.1158/1078-0432.CCR-22-0543"]}}